| 21st week of 2022 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20220160594 | PARTICULATE AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE MATERIAL - The present invention relates to a particulate highly porous amorphous mesoporous magnesium carbonate material suitable for uptake of high amounts of oily substances, sebum or a beneficial agent or combinations of these and to topical and cosmetic compositions comprising such material. The particulate highly porous amorphous mesoporous magnesium carbonate material according to the invention has a total pore volume larger than 0.1 cm 3/g and is constituted of particles having a peak particle size at or below 35 μm. | 2022-05-26 |
| 20220160595 | AN ANTIPERSPIRANT COMPOSITION COMPRISING REACTIVE SALTS - The present invention is in the field of antiperspirant compositions, in particular, compositions comprising antiperspirant actives. Disclosed is an aqueous antiperspirant composition having pH 2 to 5, comprising a phase wherein said phase comprises: (i) a water-soluble phosphate salt; and (ii) a water-soluble non-phosphate salt; wherein said water-soluble non-phosphate salt is the salt of a carboxylic acid, amino acid or a sulfonic acid; wherein said water-soluble non-phosphate salt is selected from calcium gluconate, calcium formate, calcium lactate, calcium propanoate, calcium acetate, calcium dobesilate, magnesium citrate, magnesium gluconate, magnesium acetate, magnesium lactate, magnesium malate, zinc citrate, zinc gluconate, copper (II) acetate, copper (II) gluconate, iron (III) citrate, calcium glycinate, zinc glycinate, copper glycinate, zirconium chloride glycinate, lanthanum acetate and silver acetate; wherein said water-soluble phosphate salt is selected from monosodium phosphate, disodium phosphate, trisodium phosphate, monopotassium phosphate, dipotassium phosphate, dipotassium phosphate, monoammonium phosphate, diammonium phosphate, triammonium phosphate, lithium dihydrogen phosphate, dilithium hydrogen phosphate and lithium phosphate; wherein said composition is not a dentifrice; wherein the solubility of said salt in water is assessed at 25° C. and atmospheric pressure. | 2022-05-26 |
| 20220160596 | HYDROPHILIC SILICA/POLYMER BLEND - A hydrophilic silica/polymer blend is provided comprising (a) a hydrophilic silica powder; and (b) a thickening polymer powder, comprising (i) structural units of C | 2022-05-26 |
| 20220160597 | DENTAL CALCULUS REMOVAL - Provided herein are aqueous compositions useful for softening and loosening dental calculus deposits. The compositions include high concentrations of sorbitol and minimal or no other components. Also provided are methods for using the provided compositions in the removal of calculus from a tooth surface. | 2022-05-26 |
| 20220160598 | Compositions Incorporating Avobenzone-Calix[8]-PO3H2 Complex - A novel composition is disclosed comprising the complex avobenzone-calix[8]-PO | 2022-05-26 |
| 20220160599 | Chemical Formulations and Their Use in Neutralizing or Eliminating Odors - The present invention is a chemical formulation and method of using the chemical formulation to neutralize or eliminate odors on a surface. In one aspect, the chemical formulation is an aqueous solution of multi-valent citrate salts and a surfactant that may further comprise a fragrance and/or a color and/or a chelating agent. The method comprises the steps of applying this formulation in sufficient volume to saturate the surface thereby neutralizing or eliminating the odor. In another aspect, the formulation of multi-valent citrate salts may be applied in solid form to an odorous aqueous solution or may be used to coat an absorbent matrix that is expected to receive an odorous aqueous solution. | 2022-05-26 |
| 20220160600 | SUNSCREEN COMPOSITIONS - Discloses are compositions which are suitable for use as sunscreen lotions and creams. The compositions are high oil load emulsions which exhibit both a quick-break effect, as well as physical stability at different temperature levels. Also disclosed are methods of manufacturing and using such compositions. | 2022-05-26 |
| 20220160601 | Sunscreen Compositions - Sunscreen compositions and sunscreen active ingredients are disclosed herein which comprise at least one ketone-containing UV filter and at least one primary or secondary amine wherein at least one ketone-containing UV filter and at least one primary or secondary amine react to form an imine analog of the ketone-containing UV filter wherein the imine analog has at least one property selected from the group consisting of a) is capable of extending UV protection into a visible region equal to or greater than 400 nm, b) is water resistant, and/or c) prevents or decreases skin penetration. This imine analog may be further modified to provide a substrate capable of reacting with transglutaminase or any variant thereof and/or a lysyl oxidase to bind the sunscreen composition or sunscreen active ingredient to a target of interest. Also disclosed are cosmetic or pharmaceutical preparations comprising any of the sunscreen compositions or sunscreen ingredients along with a cosmetically or pharmaceutically acceptable carrier. | 2022-05-26 |
| 20220160602 | LOW-WATER AGENTS FOR THE OXIDATIVE COLORING OF KERATIN FIBERS WITH PERBORATE, MICROBIAL GUM AND ANIONIC CELLULOSE - The object of the present disclosure is an agent for the oxidative coloring of keratinous fibers, in particular human hair, comprising | 2022-05-26 |
| 20220160603 | SKIN- OR HAIR-CLEANSING COMPOSITION CONTAINING AQUEOUS GELLING AGENT, AND METHODS FOR PRODUCING AQUEOUS GELLING AGENT AND CLEANSING COMPOSITION - A skin- or hair-cleansing composition including a component (A), which is an aqueous gelling agent represented by general formula (1) described in the specification, and a component (B), which is an anionic surfactant, wherein the component (A) presents a viscosity of an aqueous solution containing 1 mass % of at 25° C. of 1,000 to 5,000 mPa·s and a clouding point of the aqueous solution containing 1 mass % of component (A) of 60° C. to 80° C., and has a weight average molecular weight of 10,000 to 30,000; a method for producing the aqueous gelling agent and a method for producing the skin- or hair-cleansing composition are provided. | 2022-05-26 |
| 20220160604 | EMULSION COMPOSITION COMPRISING ULTRAVIOLET WAVELENGTH CONVERSION SUBSTANCE AND ORGANIC OILY PHASE THICKENER - There is provided a novel emulsified composition containing a UV wavelength conversion substance and an organic oil-phase thickener. | 2022-05-26 |
| 20220160605 | OIL-IN-WATER TYPE EMULSIFICATION COMPOSITION CONTAINING UV WAVELENGTH CONVERSION SUBSTANCE - To provide a novel oil-in-water type emulsified composition, comprising a UV wavelength conversion substance and a water-soluble alkyl-substituted polysaccharide derivative. | 2022-05-26 |
| 20220160606 | PERSONAL CARE COMPOSITION - A personal care composition exhibiting excellent cleaning qualities without the use, or inclusion, of a sulfated surfactant; while also delivering an anti-dandruff benefit. The personal care composition contains 7% to 12% sodium cocoyl alaninate; 3% to about 10% glyceryl ester; an antidandruff agent; a liquid carrier; and wherein the personal care composition is substantially free of sulfated surfactants. The sodium cocoyl alaninate to glyceryl ester ratio can be 2:1. The viscosity of the personal care composition can be 3 mPa-s to 12 Pa-s. | 2022-05-26 |
| 20220160607 | ANTI-AGING COSMETIC COMPOSITIONS - A cosmetic active agent comprising a mixture of mannose-6-phosphate and mannose is disclosed. | 2022-05-26 |
| 20220160608 | PEPTIDE FOR REDUCING HAIR LOSS AND PROMOTING HAIR GROWTH, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - The present invention relates to a peptide for reducing hair loss or promoting hair growth, and a cosmetic composition and a pharmaceutical composition comprising the same, and specifically, a cosmetic composition, and a pharmaceutical composition for treatment may be provided, which are capable of reducing hair loss and promoting hair growth by activating a Wnt/β-catenin signaling pathway, and at the same time, promoting the activity of the collagenase MMP-2 and ALP proteins and growth hormones needed for hair growth. | 2022-05-26 |
| 20220160609 | FUSION PROTEIN COMPRISING GROWTH DIFFERENTIATION FACTOR 11 AND EPIDERMAL GROWTH FACTOR WITH ENHANCED ANTI-OXIDATION ACTIVITY AND ENHANCED SKIN CELL PROLIFERATION EFFECT AND COSMETIC COMPOSITION FOR ANTI-WRINKLE COMPRISING THE SAME AS EFFECTIVE COMPONENT - A fusion protein according to an embodiment of the present disclosure includes a growth differentiation factor 11 and an epidermal growth factor with an enhanced anti-oxidation activity and an enhanced skin cell proliferation effect, A cosmetic composition according to an embodiment of the present disclosure includes the fusion protein as an effective component. The cosmetic composition can be advantageously used in future as a material of a functional cosmetic product. | 2022-05-26 |
| 20220160610 | EXOPOLYSACCHARIDE-PROTEIN COMPLEX, A METHOD OF PREPARING SAID COMPLEX AND USES THEREOF - The present invention relates to an exopolysaccharide-protein complex obtained from a bacterium comprising: (i) a crude exopolysaccharide, and (ii) exopolysaccharide-associated proteins which are derived from outer membrane vesicles and have a molecular weight between 30 and 250 kDa. The present invention further relates to a method for preparing said exopolysaccharide-protein complex and uses thereof. | 2022-05-26 |
| 20220160611 | ENHANCED SILICONE DEPOSITION COMPOSITIONS AND METHOD THEREFOR - The disclosed technology relates to stable conditioning shampoos comprising silicone oil and a fermentation derived cellulose (FDC) component. The FDC component provides good suspension of particulate and insoluble materials such as aesthetic beads and mica in surfactant-based systems, as well as enhances the deposition of silicone conditioning agents to keratinous substrates such as the hair and skin. | 2022-05-26 |
| 20220160612 | COSMETIC USE OF AMYLOSE-RICH STARCH AS FILM-FORMING AGENT WITH BARRIER AND FIXATIVE EFFECTS - The invention relates to the field of film-forming agents for cosmetic or dermatological use, that are capable of conferring a barrier effect or a fixative effect on a cosmetic preparation. The barrier effect makes it possible to protect the skin from environmental pollution, for example microparticles and volatile organic compounds, and more particularly from urban atmospheric pollution. The fixative effect makes it possible to reduce or eliminate the transfer of pigments and/or dyes, and to increase the hold of the hairstyle or the shaping of head hair, body hair or eyelashes. | 2022-05-26 |
| 20220160613 | COMPLEXION BASE CONFERRING A LONG-LASTING MAKE-UP - A complexion base in the form of an oil-in-water or water-in-oil emulsion including at least one leguminous starch having an amylose content higher than or equal to 30%, at least one plasticiser selected from polyols, at least one oil and at least one emulsifying agent and water, with the understanding that the starch is present in a dry-matter content included between 1% by weight and 25% by weight, with respect to the total weight of the complexion base. Also, the use of such a complexion base to improve holding over time of the make-up, preferably to improve the resistance to sweat and to sebum. | 2022-05-26 |
| 20220160614 | HAIR COLORANT COMPOSITIONS - The present invention relates to hair coloring and/or bleaching compositions that can be applied at less aggressive pH environment using relatively low oxidizing agent amounts, as well as their kits and methods thereof. The compositions exhibit low odor and substantially reduced hair fiber damage, are compatible with current dyes and dye precursor systems and result in excellent dye deposition with substantially no lift. | 2022-05-26 |
| 20220160615 | COSMETIC, COSMETIC FOR USE IN WARMED STATE, AND BEAUTY METHOD - To provide a cosmetic that suppresses greasiness and siphons continuously during a dispenser operation. Also, to provide a cosmetic for use in a warmed state, the cosmetic having temperature responsiveness and high high-temperature stability. The cosmetic contains (A) a hydrophobically modified polyether urethane, (B) cellulose nanofibers, and (C) water, wherein: when the blend ratio of (A) and (B) is such that (A)<(B), the amount of (A)+(B) blended is 0.75% by mass or less relative to the total cosmetic; when the blend ratio of (A) and (B) is such that (A)=(B), the amount of (A)+(B) blended is 1.75% by mass or less relative to the total cosmetic; and when the blend ratio of (A) and (B) is such that (A)>(B), the amount of (A)+(B) blended is 2% by mass or less relative to the total cosmetic. | 2022-05-26 |
| 20220160616 | BEAUTY PRODUCT COMPOSITION FOR EYEBROWS - A composition for stimulating eyebrow growth is provided. The composition includes about black Jamaican oil with lavender, about one tablespoon and about a half teaspoon raw cacao powder, about one tablespoon raw shea butter, about one tablespoon yellow beeswax, and about one tablespoon cedarwood oil. The composition may be formed in a solid form and is used as a stick. The stick may be used as a lipstick or eyebrow applicator. | 2022-05-26 |
| 20220160617 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES - Disclosed herein are compositions and methods for using human-derived | 2022-05-26 |
| 20220160618 | Pharmaceutical Formulation - The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse. | 2022-05-26 |
| 20220160619 | Effervescent Drug Formulations - The disclosure relates to an effervescent therapeutic composition for delivering multiple compounds to a patient in a single administration. In some embodiments, the effervescent therapeutic composition includes an alkaline effervescing compound, one or more compressible binders, a pharmaceutically acceptable salt of metformin, a pharmaceutically acceptable cobalamin, and an acid compound or an acid salt. In other embodiments, the effervescent therapeutic composition may include a folate or folic acid and metformin. In yet other embodiments, the effervescent therapeutic composition may include a folate or folic acid, cobalamin, and metformin. | 2022-05-26 |
| 20220160620 | FORMULATIONS FOR TREATING PSORIASIS - Disclosed herein is a topical formulation for treating psoriasis. The formulation comprises ground wheat and a wheat extract, ground barley and a barley extract, an oil and egg or a fraction thereof. Also disclosed is a method for treating psoriasis comprising applying the topical formulation to an affected area of a patient. | 2022-05-26 |
| 20220160621 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION - The present disclosure is directed to the methods of treating a patient with schizophrenia or bipolar I disorder by administering to the patient an injectable preparation of aripiprazole, wherein the patient is administered the injectable preparation about once every two months. | 2022-05-26 |
| 20220160622 | THERAPEUTIC METHODS INVOLVING GASTROINTESTINAL IMPLANTS - The present invention provides combination therapies for treating a metabolic disorder, such as type 2 diabetes, obesity, and related comorbidities (e.g., NASH or NAFLD)) in an individual undergoing treatment with a gastrointestinal implant. The combination therapies described herein include methods for treating an individual with a gastrointestinal implant with a metabolic agent, a bariatric procedure, and/or a microbiota modulator. | 2022-05-26 |
| 20220160623 | USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION - Methods of using the alpha-2-adrenergic receptor agonist of Formula I: | 2022-05-26 |
| 20220160624 | EYE DROPS CONTAINING CHITOSAN NANOPARTICLES IN WHICH PDRN IS ENCAPSULATED, AND PREPARATION METHOD THEREFOR - The present invention relates to nucleic acid fragment-encapsulated polymer nanoparticles and a method of preparing the same. The polymer may be a mucoadhesive polymer and specifically chitosan, and the nucleic acid fragment may be polydeoxyribonucleotide (PDRN). The nucleic acid fragment-encapsulated polymer nanoparticles may be used as an eye drop. Since the nucleic acid fragment-encapsulated polymer nanoparticles is capable of adhering to the mucus in the eyes, nucleic acid fragments inside the nanoparticles can be slowly released into the ocular mucous membrane. In addition, since nucleic acid fragment-encapsulated polymer nanoparticles can exhibit high efficiency in the eyes even with a small dose of drug, patient convenience can be increased or costs can be reduced. | 2022-05-26 |
| 20220160625 | METHODS AND DEVICES FOR REDUCING INTRAOCULAR OXIDATIVE DAMAGE - An intraocular antioxidant generation device is configured to be implanted within an eye. The intraocular antioxidant generation device comprises a scaffold and a generation medium coupled to the scaffold, according to various embodiments. The generation medium is configured to at least one of generate, regenerate, recycle, and produce antioxidants, according to various embodiments. | 2022-05-26 |
| 20220160626 | Oral Cannabinoid Formulations - Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. | 2022-05-26 |
| 20220160627 | ENHANCED LICORICE ROOT CHEWS - A long acting licorice root segment includes a licorice root segment infused or otherwise combined with an active agent and providing administration of the active agent to the oral cavity while the licorice root segment is in a mouth of a user. The active agent may include caffeine, a cannabinoid, or nicotine, or combinations thereof, and may also include additives such as flavorings, vitamins, mineral supplements, herbal supplements, and combinations thereof. Methods for preparing the infused licorice root segments are also described. | 2022-05-26 |
| 20220160628 | PROCESS FOR MANUFACTURING IMPROVED SEMI-SOFT SOLID DOSAGE FORMS AND SOFT CHEWS PRODUCED THEREBY - The invention relates to semi-soft dosage forms with functional health ingredients for animal as well as human use. | 2022-05-26 |
| 20220160629 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM - Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent. | 2022-05-26 |
| 20220160630 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM - An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track. | 2022-05-26 |
| 20220160631 | ANTIFUNGAL NANOPARTICLES FOR TARGETED TREATMENT OF FUNGAL INFECTIONS - The invention provides functionalized antifungal-loaded liposomal formulations targeting | 2022-05-26 |
| 20220160632 | PEGYLATED LIPOSOMES AND METHODS OF USE - Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided. | 2022-05-26 |
| 20220160633 | COMPOSITIONS FOR DELIVERY OF CODON-OPTIMIZED MRNA - The present invention provides, among other things, improved pharmaceutical compositions comprising codon-optimized mRNA encoding a peptide or polypeptide encapsulated in a lipid nanoparticle comprising one or more of the cationic lipids that are particularly effective for pulmonary delivery. | 2022-05-26 |
| 20220160634 | NANOPARTICLE COMPOSITION WITH REDUCED CONTAMINANT AND PRODUCTION METHOD THEREOF - A method for the production of the present disclosure comprises: a) a step of agitating a mixture containing a material to be ground, beads and a dispersion medium in a bead mill; and b) a step of adjusting the pH of the mixture. | 2022-05-26 |
| 20220160635 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT - Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations. | 2022-05-26 |
| 20220160636 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT - Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations. | 2022-05-26 |
| 20220160637 | LYOPHILIZED FORMULATIONS OF TEGAVIVINT - Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations. | 2022-05-26 |
| 20220160638 | LYOPHILIZATION OF RNA - The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention. | 2022-05-26 |
| 20220160639 | MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) - The present invention relates to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD) or attention deficit/hyperactivity disorder (ADHD) or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults. | 2022-05-26 |
| 20220160640 | ALCOHOL-RESISTANT DRUG FORMULATIONS - The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus. | 2022-05-26 |
| 20220160641 | CAPSULE WITH INTERNAL DIAPHRAGM FOR IMPROVED BIOAVAILABILITY - A multi-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an oil. A two-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an oil, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an ingredient. The ingredient may have increased bioavailability after exposure to the oil. This disclosure also provides particular formulations for use in such a capsule. | 2022-05-26 |
| 20220160642 | CAPSULES AND CAPSULE COATINGS FOR GASTRIC RESIDENCE DOSAGE FORMS - Provided are gastric residence dosage forms comprising: a gastric residence system in a folded configuration; a capsule encapsulating the gastric residence system in a folded configuration; and a coating on the capsule, wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration. The coating on the capsule includes a polymer, an anti-tacking agent, and/or a hydration aid. | 2022-05-26 |
| 20220160643 | CHITOSAN-COATED PLATINUM FERRITE-SILICA SPINEL NANOCOMPOSITE - Chitosan can be coated, e.g., in 0.06 or 0.6 wt. %, over spherical silica, e.g., HYPS, loaded with spinel ferrites of theoretical formula MFe | 2022-05-26 |
| 20220160644 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY - A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug. | 2022-05-26 |
| 20220160645 | NANOPARTICLES COMPRISING COPOLYMERIC OR HOMOPOLYMERIC COMPOUNDS WHICH COMPRISE CYANOACRYLATE SUBUNITS - The invention relates to a nanoparticle comprising copolymeric or homopolymeric compounds which comprise cyanoacrylate subunits according to formula 2A, wherein each R | 2022-05-26 |
| 20220160646 | ORAL THIN FILM - Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament. | 2022-05-26 |
| 20220160647 | TRANSDERMAL DRUG DELIVERY DEVICE/TRANSDERMAL PATCH AND OTHER APPLICATIONS OF EMULSION FORMULATION - The present disclosure relates to a transdermal drug delivery device, also known as a transdermal patch that can be worn by the user anywhere the person travels throughout the day. The transdermal patch is characterized in that it is a single-layered patch comprising an liposomal emulsion carrying a drug to be administered and an adhesive which are both incorporated into a polymer or polymeric matrix. The liposomal emulsion within the single-layered transdermal patch allows the drug that is to be administered to be spread throughout the entire surface area of the transdermal patch. | 2022-05-26 |
| 20220160648 | Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof - Composition comprising enzymatically hydrolyzed collagen and cannabidiol, the composition suitable for ingestion by an individual to facilitate improvements in rest, including sleep, and/or in recovery, including but not limited to recovery after physical and/or mental exertion, recovery from pain and combinations thereof, and to facilitate improved delivery to the individual of amino acids comprised in the enzymatically hydrolyzed collagen. Both liquid and particulate compositions comprising full spectrum cannabidiol oil or cannabidiol isolate are provided as well as compositions comprising one or more of a terpene isolate, flavonoid, essential oil, effervescent agent, sweetener or flavoring agent. | 2022-05-26 |
| 20220160649 | PHARMACEUTICAL COMPOSITION - The invention relates to a pharmaceutical composition comprising fulvic acid, a resveratrol derivative, optionally at least one boron-containing compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, in particular for the treatment or prevention of inflammatory skin disorders. | 2022-05-26 |
| 20220160650 | GEL, OINTMENT, AND FOAM FORMULATIONS OF TAPINAROF AND METHODS OF USE - Embodiments described herein relate to topical pharmaceutical compositions comprising tapinarof, wherein the topical pharmaceutical composition is formulated as an aqueous gel, an anhydrous gel, an ointment, or a foam. Embodiments also relate to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient. | 2022-05-26 |
| 20220160651 | RAPIDLY IMPROVING ENDOTHELIAL FUNCTION, REDUCING ARTERIAL STIFFNESS AND REVERSING CALCIFICATION OF BLOOD VESSELS BY ADMINISTERING VITAMIN K - A method for rapidly improving cardiovascular function, reducing arterial stiffness and reversing calcification of a blood vessel in a mammal comprising administering to the mammal an effective amount of vitamin K for a period of 2 weeks to less than 6 months. Also a method for increasing endothelial nitric oxide production in mammals comprising administering to the mammal an effective amount of vitamin K for a period of 2 to 8 weeks. The vitamin K can be administered together with additional substances such as vitamin D. | 2022-05-26 |
| 20220160652 | USE OF VITAMIN K IN COMBINATION WITH ANTICOAGULANTS - A method of treating or preventing a condition characterized by unacceptable blood clotting and/or an increased risk thereof, the method including administering to a subject in need thereof a combination of vitamin K2 and at least one anticoagulant, the at least one anticoagulant having a first anticoagulant configured to inhibit free Factor Xa and/or Factor Xa bound in a prothrombinase complex of the subject. | 2022-05-26 |
| 20220160653 | Preparation Method For Carotenoid Preparation Having High Bioavailability And High Stability - The present invention provides a preparation method for a carotenoid preparation having high bioavailability and high stability, comprising the following steps: a) dissolving part of a water-soluble colloid and a filling substance in water to form an aqueous phase; b) adding a carotenoid crystal to the aqueous phase and stirring for dispersion so as to form a dispersion liquid; c) loading the dispersion liquid into a first-stage grinding machine for first grinding to form a first-stage grinding liquid; d) adding the remaining water-soluble colloid and filling substance to the first-stage grinding liquid, loading same into a second grinding machine for secondary grinding to obtain a second-stage grinding liquid; and e) drying the moisture in the second-stage grinding liquid to obtain carotenoid dry powder or particles. | 2022-05-26 |
| 20220160654 | COMPOSITION FOR STIMULATING MUSCLE GROWTH, REPAIR, AND MAINTENANCE - The present invention relates to a composition for stimulating muscle growth, repair and maintenance and the method of using the same. The present invention generally relates to compositions and methods for supporting muscle anabolism. The compositions described herein are pharmaceutical or nutritional compositions suitable for preserving muscle mass, strength, and/or function in a subject in need thereof. The compositions are based on a specially formulated mixture of essential amino acids (EAAs) and protein with additional components. Use of the compositions herein may prevent muscle atrophy associated with periods of rest, such as those following surgery, injury, inactivity and during recovery from disease. | 2022-05-26 |
| 20220160655 | ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE - A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The NMDA receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. Instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. The administration of the NMDA receptor antagonist composition is particularly useful as a premedication for adults. | 2022-05-26 |
| 20220160656 | INTRANASALLY ADMINISTERED ANTIHISTAMINES AND USES THEREOF - Disclosed herein are compositions including diphenhydramine, or a pharmaceutically acceptable salt thereof, and a liquid vehicle. The compositions may be administered intranasally to patients in need of diphenhydramine. The compositions provide increase plasma and brain concentrations relative to orally administered compositions, but without the limitations associated with intravenously administered compositions | 2022-05-26 |
| 20220160657 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS - Pharmaceutical compositions of epinephrine and its prodrugs are described, the prodrugs having a half-life of less than one minute, and the compositions having enhanced active component permeation properties are described. | 2022-05-26 |
| 20220160658 | TESOFENSINE FOR REDUCTION OF BODY WEIGHT IN PRADER-WILLI PATIENTS - The present invention relates to a method of reducing body weight or hyperphagia in Prader-Willi patients comprising administering the active compound Tesofensine or a pharmaceutically acceptable salt thereof, preferably by the administration of a controlled release formulation comprising the active compounds tesofensine and a beta blocker. The invention further relates to pharmaceutical compositions comprising no more than 0.150 mg of Tesofensine, or a pharmaceutically acceptable salt thereof, and no more than 25 mg Metoprolol | 2022-05-26 |
| 20220160659 | PHARMACEUTICAL COMPOSITION COMPRISING a-GALACTOSYLCERAMIDE AND/OR DENDRITIC CELLS PULSED WITH a-GALACTOSYLCERAMIDE - The present invention pertains to a pharmaceutical composition comprising α-galactosylceramide and/or dendritic cells pulsed with α-galactosylceramide, said pharmaceutical composition being for preventing and/or treating drug-induced myocardial dysfunction. The present invention also pertains to a pharmaceutical composition comprising α-galactosylceramide and/or dendritic cells pulsed with α-galactosylceramide, said pharmaceutical composition being to be administered to a subject, who develops drug-induced myocardial dysfunction or is at a risk of developing the same, before and after administering the drug that is likely causative of the drug-induced myocardial dysfunction. | 2022-05-26 |
| 20220160660 | DEUTERATED FORMS OF ACETAMINOPHEN AND USES THEREOF - The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen. | 2022-05-26 |
| 20220160661 | SOLID-FORMING TOPICAL FORMULATIONS FOR PAIN CONTROL - Methods of applying a solid forming local anesthetic formulations can include applying a layer of a solid-forming formulation to a skin surface, wherein the solid-forming local anesthetic formulation includes from 4 wt % to 30 wt % of a local anesthetic, less than 36 wt % dicalcium phosphate, water, and a polymer. These methods can further include maintaining the layer of the formulation on the skin surface for a period of time sufficient to allow the layer of the formulation to transition from a semi-solid to a cohesive film and to topically deliver the local anesthetic to the skin surface, and removing the layer of the formulation from the skin surface by peeling the layer of the formulation off the skin surface. The layer of the formulation can be operable to be removed as a single piece or two to three large pieces. | 2022-05-26 |
| 20220160662 | COMPOUNDS AND METHODS FOR TREATING ABERRANT ADRENOCORTICAL CELL DISORDERS - Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient. | 2022-05-26 |
| 20220160663 | Immunosuppressant Comprising TSAHC or a Pharmaceutically Acceptable Salts Thereof as an Active Ingredient - The present invention relates to an immunosuppressant comprising TSAHC or a pharmaceutically acceptable salt thereof as an active ingredient. TSAHC treatment suppressed the expression and secretion of cytokines/chemokines such as IL6, IL1β, TNFα, CXCL1, CXCL2, CXCL3, CXCL6, CXCL8, CCL2, CCL5, CCL20, CXCL10 and CCR10 according to the expression of TM4SF5 gene and protein, and the cytokines or chemokines mediated by the expression of TM4SF5 induced abnormalities in the inflammatory response and metabolic function of liver tissues, hepatic epithelial cells and macrophages, and correlated with liver tissue damage and immune cell recruit in TM4SF5 transgenic animals. Therefore, a composition comprising TSAHC or a pharmaceutically acceptable salt thereof as an active ingredient can be effectively used as an immunosuppressant. | 2022-05-26 |
| 20220160664 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS - Provided are compositions and methods comprising a TAZ activator and a Wnt agonist for increasing proliferation of cochlear supporting cells or vestibular supporting cells, and related methods of treating inner ear hearing or balance disorders. | 2022-05-26 |
| 20220160665 | COMPOSITION IN MICRO-ENCAPSULATED FORM, BASED ON N-BUTYRICACID OR DERIVATIVES THEREOF, FOR TREATING CROHNS DISEASE OR ULCERATIVE RECTAL COLITIS - A composition in micro-encapsulated form, comprising a core based on n- butyric acid or a derivative thereof, and a coating based on a lipid matrix which surrounds the core, in which the matrix has a content of C14-C22 long chain saturated fatty acids between 40% and 95%, is used for the treatment of ulcerative rectal colitis or Crohn's disease. | 2022-05-26 |
| 20220160666 | COMPOSITIONS FOR USE IN SURGERY - A method is provided for treating a subject in need of medication as an adjunct to elective surgery, comprising administration of a ketogenic material sufficient to produce a physiologically acceptable ketosis in the patient. Preferably the surgery is selected from the groups consisting of removal or section of tumours, removal of redundant organs such as lymph nodes and appendix, open heart surgery, cosmetic surgery, joint and bone surgery. | 2022-05-26 |
| 20220160667 | Topical Gel Compositions of Naproxen - The present disclosure relates generally to topical analgesic compositions comprising nonsteroidal anti-inflammatory drugs, and more specifically to topical gel compositions of naproxen in combination with select neutralizing agents, thereby having enhanced skin permeation and skin retention properties as well as improved aesthetics upon application and drying. | 2022-05-26 |
| 20220160668 | FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE - The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis. | 2022-05-26 |
| 20220160669 | PARENTERAL NUTRITION FORMULATION - A composition for use in the treatment of a patient suffering from or being at risk of developing a gastrointestinal disorder is disclosed. The composition is an aqueous solution for injection comprising arginine butyrate in a concentration of from 150 mg/L to 5500 mg/L of the composition. A method of treating a patient suffering from or being at risk of developing a gastrointestinal disorder by administering the related compositions is also disclosed. | 2022-05-26 |
| 20220160670 | COMPOSITION COMPRISING L-CARNITINE FOR THE TREATMENT OF MALE INFERTILITY - The invention relates to a composition for the treatment of male infertility. The invention is characterized by a composition comprising L-carnitine and/or acetyl-L-carnitine or prodrugs thereof for the treatment of infertility in men with a sperm concentration of less than 5 million spermatozoa per milliliter. | 2022-05-26 |
| 20220160671 | ANTIVIRAL THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR USE IN TREATMENT OF CORONAVIRUS AND INFLUENZA VIRUS - Antiviral therapeutic compounds and compositions that may be used in methods of preventing and/or treating infection(s) caused by coronaviruses or influenza viruses. | 2022-05-26 |
| 20220160672 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF - The invention relates to a pharmaceutical composition comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. | 2022-05-26 |
| 20220160673 | METHOD PREPARING SILVER-NANOCURCUMIN MATERIAL FOR INHIBITING NEW CORONAVIRUS - The present disclosure provides a method preparing Silver-nanocurcumin material for inhibiting new coronavirus. The turmeric powder is heated and stirred and then mixed with silver nitrate solution. After multiple steps of cooling, stirring for reaction and centrifuging and other steps, crude extract of Silver-nanocurcumin is obtained. Then, after further processes such as the multiple washing and centrifuging, a purified composition of Silver-nanocurcumin is obtained. The composition of Silver-nanocurcumin can be used to inhibit the new coronavirus and its similar viruses, and as a source of drugs for the prevention and treatment of diseases derived from the new coronavirus COVID-19 in the future. | 2022-05-26 |
| 20220160674 | Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance - Ophthalmic formulations for acute and transient treatment of night vision disturbance syndrome (NVD) are presented. Preferred formulations comprise carbachol at very low concentrations that were demonstrated to unexpectedly provide an acute and transient therapeutic effect for a desirable magnitude and period of time. | 2022-05-26 |
| 20220160675 | ORAL CANNABINOID PRODUCT WITH LIPID COMPONENT - Meltable compositions configured for oral use, the compositions including at least one cannabinoid or cannabimimetic, are provided. The compositions include one or more fillers, typically a sugar alcohol, and a lipid. A method of forming such compositions is also provided. | 2022-05-26 |
| 20220160676 | USE OF 3-O-SULFAMOYLOXY-7Beta-METHYL-D-HOMO-6-OXAESTRA-1,3,5(10),8(9)-TETR- AEN-17A-ONE TO TREAT BREAST CANCER - The invention relates to the field of medicine and to the chemical and pharmacological industry, and concerns medicaments for the treatment of breast cancer. In particular the invention relates to a use of 3-O-sulfamoyloxy-7β-methyl-D-homo-6-oxaestra-1,3,5 (10),8(9)-tetraen-17a-one as an anti-cancer agent in monotherapy and adjuvant therapy of breast cancer, including the triple negative breast cancer. | 2022-05-26 |
| 20220160677 | TUMESCENT INFILTRATION DRUG DELIVERY OF CANNABINOIDS - A tumescent composition including a cannabinoid dissolved in a tumescent solution, wherein the tumescent solution includes a local anesthetic; a vasoconstrictor; and a pharmaceutically acceptable carrier, wherein a tumescent concentration of the cannabinoid is 1-2000 μg/kg and is simultaneously: below a threshold for local, subcutaneous tissue toxicity, above a threshold for positive local therapeutic effect, and above a concentration safely achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery. Also disclosed are methods of subcutaneous delivery of a cannabinoid to a subject including administering to the subject the tumescent composition. | 2022-05-26 |
| 20220160678 | MODULATION OF MOLECULAR MARKERS USING S-EQUOL - The present invention provides methods and compositions for modulating molecular markers, and hence treating or preventing breast cancer (e.g., triple-negative breast cancer) and melanoma with a pharmaceutically effective amount of S-equol or a pharmaceutical composition comprising S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule. | 2022-05-26 |
| 20220160679 | COMPOSITIONS AND METHODS FOR CANCER THERAPY - The invention provides compositions and methods to treat relapsed multiple myeloma with pharmacological ascorbic acid or a pharmaceutically acceptable salt thereof, and one or more anti-cancer therapies. | 2022-05-26 |
| 20220160680 | MICROORGANISM MIXTURES, MOLECULES DERIVED THEREFROM, AND METHODS OF USE THEREOF - The present invention is directed to a composition comprising a Tryptophol derivative and a 4-Ethyl-Phenol derivative, and at least one acceptable carrier. Further provided are methods for reducing the formation of load of organic-based contaminant. | 2022-05-26 |
| 20220160681 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain compositions of a 5-HT | 2022-05-26 |
| 20220160682 | SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXIS - Disclosed herein are methods of treating or preventing infections associated with organisms, or preventing vector-borne diseases including | 2022-05-26 |
| 20220160683 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION - The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder. | 2022-05-26 |
| 20220160684 | Extended Release Methazolamide Formulation - A once-a-day controlled release oral dosage form of methazolamide is provided. The dosage form comprises a therapeutically effective amount of methazolamide and a high molecular weight binder. The dosage is configured for once-daily administration to a subject in need thereof, and releases methazolamide over a period of about twenty-four hours. | 2022-05-26 |
| 20220160685 | LOW-TEMPERATURE SYNTHESIS OF THYMOQUINONE AND HARMALINE COMPOUNDS - Low-temperature syntheses of thymoquinone/harmaline compounds which are useful for the treatment of human diabetes and cancers, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds. | 2022-05-26 |
| 20220160686 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS - The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: | 2022-05-26 |
| 20220160687 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy. | 2022-05-26 |
| 20220160688 | INHIBITION OF NAMPT AND/OR SARM1 FOR THE TREATMENT OF AXONAL DEGRADATION - This invention relates generally to diseases and conditions characterized with axonal degradation and, more particularly, to methods and compositions for treating or preventing traumatic or degenerative neuropathies and other diseases and conditions involving axonal breakdown/degeneration. | 2022-05-26 |
| 20220160689 | COMPOSITIONS AND METHODS FOR PAIN RELIEF AND NUMBING - Compositions containing an anesthetic and an extracellular matrix component or fragment thereof and methods for treating pain by topically administering such compositions are described herein. | 2022-05-26 |
| 20220160690 | Methods for Treatment of Fabry Disease - Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone. | 2022-05-26 |
| 20220160691 | Methods Of Treating Fabry Patients Having Renal Impairment - Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day. | 2022-05-26 |
| 20220160692 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER - Immune checkpoint blockade therapy is based on the inhibition of the tumor-mediated suppression of anticancer immune responses. However, the efficacy and effectiveness of said therapy vary greatly across individual patients and among different tumor types. A substantial unmet need is thus to identify novel targets that can enhance the therapeutic efficacy of the immune checkpoint blockade therapy. S1P is produced by sphingosine kinases (i.e. SK1 and SK2) that catalyze the phosphorylation of sphingosine to SIP. SK2 inhibitors were described as suitable for the treatment of cancer. However the role of SK2 in the immune tumor microenvironment has never been investigated. The inventors now showed that genetic deletion of SPHK2 leads to a delay in the melanoma tumor growth and an increase in tumor-infiltrating effector lymphocytes. In particular the increase of tumor-infiltrating effector lymphocytes in the tumor is associated with a decrease in the amount of tumor-infiltrating myeloid-derived suppressor cells. Moreover, the combination of SPHK2 deficiency with immune-checkpoint blockade leads to tumor rejection and increases survival rate. Accordingly, the present invention relates to use of SK2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer. | 2022-05-26 |
| 20220160693 | PHARMACEUTICAL COMPOSITION OF PROLYL HYDROXYLASE INHIBITOR AND PREPARATION METHOD THEREFOR - The present application provides a pharmaceutical composition of a prolyl hydroxylase inhibitor and a preparation method therefor. In particular, the present application provides a composition comprising a compound represented by formula (I) or a pharmacologically acceptable salt thereof and at least one water-soluble filler. The composition provided by the present application has a rapid dissolution rate and good stability. | 2022-05-26 |
